STOCK TITAN
  1. Home
  2. Sec-filings
  3. CINGW
  4. [S-1] Cingulate Inc. Warrants Files IPO Registration Statement

[S-1] Cingulate Inc. Warrants Files IPO Registration Statement

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
S-1
Rhea-AI Filing Summary
Analyzing...
Positive
  • None.
Negative
  • None.

Filing content is currently unavailable.

Source: View Original Filing on SEC EDGAR

Stock CINGW logo
Cingulate

NASDAQ:CINGW

CINGW Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

CINGW Latest News

Jul 9, 2025
Cingulate Appoints Nilay Patel as Chief Legal Officer to Support Growth ahead of New Drug Application
May 20, 2025
Efficacy Results Announced from Cingulate’s Phase 3 Pediatric Study of CTx-1301 (dexmethylphenidate) for ADHD
May 14, 2025
FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301
May 8, 2025
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Apr 29, 2025
Cingulate Announces Positive Top-Line Results from High-Dose (50mg) Fed/Fast Study of Lead Asset CTx-1301 for ADHD

CINGW Latest SEC Filings

Jul 22, 2025
[8-K] Cingulate Inc. Warrants Reports Material Event
Jul 10, 2025
[Form 4] Cingulate Inc. Warrants Insider Trading Activity
Jul 10, 2025
[Form 3] Cingulate Inc. Warrants Initial Statement of Beneficial Ownership
Jul 9, 2025
[Form 4] Cingulate Inc. Warrants Insider Trading Activity
Jul 9, 2025
[Form 4] Cingulate Inc. Warrants Insider Trading Activity

CINGW Stock Data

3.83M
Biotechnology
Pharmaceutical Preparations
Link
United States
KANSAS CITY